Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milan J Sonneveld

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Milan J Sonneveld, Harry L A Janssen
Current Hepatitis Reports|May 13, 2010
Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis BMilan J Sonneveld, Harry L A Janssen
Journal of Hepatology|December 15, 2025
Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyondMilan J Sonneveld, Harry L A Janssen
Antiviral Therapy|August 18, 2012
Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavirMilan J Sonneveld, Roeland Zoutendijk, Bettina E Hansen, et al.
Hepatology (Baltimore, Md.)|May 20, 2025
Management of Immune Tolerant Chronic Hepatitis BMai M Kilany, Milan J Sonneveld, Jordan J Feld, et al.
Journal of Hepatology|February 5, 2013
Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis BMilan J Sonneveld, Pauline Arends, Andre Boonstra, et al.
ACG Case Reports Journal|February 12, 2020
Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With TocilizumabMilan J Sonneveld, S Darwish Murad, A A van der Eijk, et al.
Hepatology (Baltimore, Md.)|September 11, 2010
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen declineMilan J Sonneveld, Vincent Rijckborst, Charles A B Boucher, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 6, 2014
[Reversibility of hepatic fibrosis]Adriaan J van der Meer, Milan J Sonneveld, Jeoffrey N L Schouten, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2012
Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment responseMilan J Sonneveld, Roeland Zoutendijk, Hajo J Flink, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Milan J Sonneveld, Harry L A Janssen
Current Hepatitis Reports|May 13, 2010
Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis BMilan J Sonneveld, Harry L A Janssen
Journal of Hepatology|December 15, 2025
Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyondMilan J Sonneveld, Harry L A Janssen
Antiviral Therapy|August 18, 2012
Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavirMilan J Sonneveld, Roeland Zoutendijk, Bettina E Hansen, et al.
Hepatology (Baltimore, Md.)|May 20, 2025
Management of Immune Tolerant Chronic Hepatitis BMai M Kilany, Milan J Sonneveld, Jordan J Feld, et al.
Journal of Hepatology|February 5, 2013
Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis BMilan J Sonneveld, Pauline Arends, Andre Boonstra, et al.
ACG Case Reports Journal|February 12, 2020
Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With TocilizumabMilan J Sonneveld, S Darwish Murad, A A van der Eijk, et al.
Hepatology (Baltimore, Md.)|September 11, 2010
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen declineMilan J Sonneveld, Vincent Rijckborst, Charles A B Boucher, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 6, 2014
[Reversibility of hepatic fibrosis]Adriaan J van der Meer, Milan J Sonneveld, Jeoffrey N L Schouten, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2012
Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment responseMilan J Sonneveld, Roeland Zoutendijk, Hajo J Flink, et al.
Pageof 8